Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Surgical Science Sweden, Audiocast, Q1'26

By Inderes5/20/2026, 9:00 AM
Surgical Science Sweden

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Tom Englund
00:01 - 11:12

Hi, everyone, and welcome to this earnings call for Surgical Science for the first quarter of 2026. My name is Tom Englund. I'm the CEO. And with me today I have Anna Berry, our CFO. We'll start with a walkthrough of quarter one and the numbers. And then we'll open up for questions. So quarter one is a quarter with two stories running in parallel. On the surface, reported sales are down 6% to 236 million SEK. But once you strip out the currency headwind that we had and the dollar moved significantly against us, the underlying business grew by 4%. And if you look at cash flow, we generated 65 million SEK from operations, which is a very strong number and significantly better than the same quarter last year. So the business itself is in good shape. Adjusted EBIT came in at 28 million or 12%. That's in line with last year. And when you adjust for currencies, it's actually around 16% right at our target level. The headwind here is, as with the revenue, almost entirely a currency story and not an operational one. Throughout the quarter, we're executing on the strategy we laid out at the Capital Markets Day in December. And I feel good about where we're headed. Now I want to take you through the different parts of the business. Educational Products grew by 6%, or 14% in local currencies. And there are some exciting things happening here that I want to highlight. EMEA had an exceptional quarter. Revenue was up over 80%, driven by a number of strong deals across Eastern Europe and the UK, which, as you know, is where our Surgical Science UK team operates, posted one of its best quarters ever. Sales in pounds sterling for the quarter actually exceeded the total for all of 2025, which is a big statement. And it also tells me that the investment that we have made in building that business is starting to pay off in a meaningful way. The Americas is a different story right now. We were down about 10% in local currency, and we see a trend in Americas with our active customers that despite pipelines being full, the purchasing decisions by our customers take a slightly longer time. There is a certain hesitation in the market, particularly in the US, and we think it's tied to the broader macro environment. The silver lining, though, is that the activity is still very high with big pipelines, as I said, especially within ultrasound and robotics, which gives us confidence that the demand is there. China deserves a specific mention. The government in China is actively pushing to support locally operated and manufactured companies, which creates a headwind for our simulator business in particular. As a result, Chinese sales declined during quarter one compared to the same quarter last year. However, we are not standing still, and we are taking concrete steps to address this, but it's a structural shift that we need to navigate carefully. The quarter saw several important product launches within our Endovascular simulation portfolio for pulmonary embolism and ICE 3D, or three-dimensional Intracardiac ultrasound. The product and R&D teams are working with an exciting product pipeline, with the aim of broadening and improving our strong portfolio even further, and also to increase the penetration in this very under-penetrated market. I want to speak a bit about ultrasound. Ultrasound had a strong quarter, and I'm particularly pleased with the momentum that we're seeing in ultrasound. The adoption of ultrasound across clinical settings is accelerating, and we're well positioned to capture that. Women's health continues to be a big and key focus for us, and I think it's worth pausing on why ultrasound is one of the primary tools for diagnosing conditions that disproportionately affect women, and it has historically been under-resourced in terms of training. Our solutions are genuinely making a difference, helping clinicians diagnose earlier with more confidence. That's directly in line with the purpose of Surgical Science. The ultrasound simulation market is also genuinely exciting from a financial perspective; due to the high number of potential users and the large size of the potential market, ultrasound simulation has the opportunity to represent an even larger share of Surgical Science's revenues in the future. A milestone this quarter was that we launched the first products built on the shared technology platform between Surgical Science and Surgical Science, UK, or formerly Intelligent Ultrasound. This is the first tangible output from R&D, from the integration of Intelligent Ultrasound, and it's a meaningful step. There is still plenty of integration work ahead, but the direction is clear and we're moving really fast. Now to robotics, where the headline number requires some context. Industry revenues were down 17% and license revenue came in at 68 million SEK versus 84 million SEK in quarter one last year. If you look at revenue in local currency, though, the license revenue was only $600,000, or 8% lower than quarter one of 2025. License revenues in quarter one in USD were actually higher than two out of four quarters of 2025. As we have previously communicated, the Memorandum of Understanding with Intuitive did not result in a signed agreement and we reverted back to our existing contract at the start of the year. We previously estimated a 60 to 90 million negative impact on license revenues for 2026 versus 2025, and that estimate remains unchanged. I want to be clear about what this is and what it is not. It is not a deterioration of relationship with Intuitive. Quite the opposite. The collaboration is as strong as it has ever been. What's changed is the commercial structure reverting back to an old agreement, and we're working within that. Our conviction remains that simulation will be a central component of the digital offerings in the robotic platforms of the future, and Surgical Science will be at the heart of that. On a market level, the picture is really exciting. The robotics market is very dynamic and fast growing. Intuitive received FDA approval for cardiac procedures. Johnson & Johnson received regulatory classification for its Ottava system. Medtronic received US approval for Hugo in Urology, and the commercial competition in the US market for robotic surgery is now real. And that's actually a good thing for Surgical Science because it means more robots, more training needs, and more licenses. We also had license revenues from several of our other robotic customers during the quarter, which is a clear sign that players beyond Intuitive are now deploying robots at scale. We are developing simulation solutions for most of the top 20 robotics companies. Our pipeline is bigger than it's ever been, and the long-term opportunity here is very big. Medical Device had a quieter quarter financially. Development revenue at 14 million. Second, simulator sales of 20 million SEK. This is a business that moves in lumps. Projects have long lead times. The comparison last year was particularly tough because several customers undertook large-scale fleet upgrades at the same time. We have a clear, high ambition within this segment and definitely a growth strategy, and we expect to show solid growth in the future. We should not judge success on one quarter alone and look too much at lag indicators. Rather, the underlying lead indicators remain strong. More than 70% of customers in active development projects are repeat clients. That's a loyalty and retention number that tells you about the quality of what we deliver. We're working with many of the biggest medtech customers globally and are a critical supplier in their deliveries, and we continue to see new clients entering as well. The foundation is solid. As outlined in the strategy, we have a strong focus on improving our gross margins, and we are seeing the effects of our work on pricing. The work that we have done here continues to deliver. However, the effects of our price increases are countered by the currency headwind that we have had since so much of our sales is in US dollars. We pushed through another price increase in April. The full effect will show up gradually as sales cycles close throughout the year, but the trend is positive and gives us confidence in margin improvement ahead. Let me step back and talk about where we're going. The strategy we laid out in December is about becoming a company that truly addresses the full potential of medical simulation across five segments, all of which have very low penetration today. And we are in the early innings of a long game. We have no debt and we have 668 million in cash. We have the market leading position. We have the products, we have the relationships, and we have the clinical expertise. This combination is genuinely rare, and it gives us real options to invest in growth, to pursue acquisitions, and also to return capital when the timing is right. In quarter two, aside from the work, with growing these five segments, we will put significant focus on our operational and and production structure, particularly on how we scale manufacturing in a way that reduces cost per unit and makes us more resilient to supply chain disruptions. Our new production facility in Tel Aviv is expected to go live during the quarter, which is going to be an important milestone for us. The tailwinds are real, and they are growing: an aging population, increasingly complex procedures, a shortage of trained healthcare professionals, higher standards for patient safety. All of these are driving demand for simulation every single year. We're building for that world, and I'm confident that we have the right strategy, the right team and the right assets to get there. With that, I will hand over to Anna to walk through the financials.

Anna Berry
11:13 - 25:25

Thank you Tom. We're very pleased to report a solid start to the year for the quarter. Then we had sales of 235 million, down 6% sequentially but up 4% in local currencies. And we have after Q1 2025 seen a significant negative effect from currencies on our overall sales and also on our result. I will come back to that later, as just below 80% of our revenues in 2025 were in US dollars. For the full year, the average USD rate was down 7%. And so of course, that affects us. And so, of course, that affects us. As I have mentioned before, we are doing some things to try and mitigate this. We are raising prices and as Tom mentioned, we did one more price increase in April, and we also try and quote more countries in euros instead of in US dollars where this is possible. This will not mean a very large change in the ratio between different currencies, since a lot of our revenues originate from the US. But for Q1, we saw approximately 70% of our revenues in US dollars. So it's down approximately seven percentage points if we compare to the full year 2025. And looking at our two business areas for the quarter, the split was 55% for Educational Products and 45% for Industry. Educational Products was up a strong quarter, up 6% or 14% in local currencies. For this year, we have updated our revenue segment somewhat. The geographic regions have been adjusted slightly, and sales by product segment have replaced sales by product group. And this is done in line with the segments that we have presented in our new strategy. Apart from the emergency medicine segment, which is still too small to be reported separately, we have therefore now included it in the medical device segment. So, back to regions. Tom already discussed this. EMEA was very, very strong, up over 80%, and the Eastern European countries accounted for the majority of this increase. And then the UK had a quarter that was stronger than any other quarter in 2025. Revenue in the Americas was down by 24% compared to Q1 last year, primarily related to the US. But excluding currency effects, sales for this region decreased by 10%. APAC saw a 25% decline, primarily attributable to China. Also, we had a large order for Pakistan in the prior year quarter. India was also strong for this quarter. India down 17%, or 7% excluding FX effects and license revenues. As Thomas talked about, 68 million, a decrease of 19% in SEK, but down 8% FX-adjusted. And if we look at our revenue streams, this means that 29% of our revenues were license revenues in the quarter. Which we see as a good number. And again, it was as expected that Intuitive was down due to the previously announced MOU cancellation, reverting back to the old agreement between the companies starting January 1st, and the previous estimate we had that this would have a negative impact on our license revenues of 60 to 90 million. That is still our best estimate. However, we also had revenues from several other countries and customers in this quarter. Simulator sales as a whole were down 2% compared to Q1 last year, and this is then due to our Industry business area. As Thomas said, it's more lumpy for sales than within our Industry, since it's usually tied to larger projects where development is also involved, and our development revenues, they were up a bit compared to last year, but weaker than the previous three quarters. This is primarily due to the project we have in a Southeast Asian country. This project saw revenues of only 2 million SEK in this quarter due to a minor restructuring of one of the project's milestones. The total for the project is still the same, even with a minor adjustment, but for this quarter we saw some weaker revenues. Moving on to our costs and EBIT margin. As mentioned, our gross margin for the quarter was 66%. 69. If we look at the comparable quarter license revenues, as we've seen a lower share of total sales, and then the currency effects, that effect was approximately 2.2 percentage points in the quarter. And here it's important to note that the lower dollar exchange rate has for us less impact on the cost of goods sold than on other cost items. Our input goods are primarily purchased in currencies other than US dollars, and production and associated wage costs are also not in US dollars. This also has a dampening effect on the gross margin. And this also has a dampening effect on the gross margin. So these three are the main three reasons. And then on the positive side, we have the price increases that we implemented in 2025. And as mentioned, we did another one in April. Regarding opex, sales costs were 21% of sales, an increase compared to the comparative quarter. We had some restructuring costs attributable to the acquisition of Intelligent Ultrasound. Surgical Science. UK. And then we also did some further restructuring in Q3. And then starting in Q4 last year, the reductions that we implemented in the sales force following the acquisition started to have full effect on the cost side. Tariffs from the US implemented in Q2 last year, meaning that we had no costs for this in the comparable quarter, Q1 last year. And for this quarter then tariffs amounted to approximately 2.4 million SEK. Admin costs 8% of sales, same as Q1 last year. If we exclude acquisition costs for IU in the comparable quarter in absolute numbers, admin costs were down. If we compare to previous quarters, we have started to work on the real estate process. But these costs. We will, of course, inform about the costs we have for each quarter due to this process, and we expect the Relisting to take place next year. R&D costs 24% of sales. We activated 9 million, slightly less than 10 million, in the quarter. The costs on this line also vary depending on how much development revenue there is for the quarter, because salaries for the portion of the development team that have worked on projects that generate development revenue are transferred to cost of goods sold, influencing the absolute R&D costs. We were down a bit compared to last quarter Q4. However, we also had some restructuring costs on this line, 3 million SEK, related to the termination of development personnel in Seattle. On the other hand, we had more development revenues than in Q4. Meaning more costs were moved to the cost of goods line. But all in all, if we look at all these different items, our R&D costs were down a bit compared to Q4, even though we continue to invest in this area. The other operating income and expense line that mainly consists of costs for the company's option programs, as well as the revaluation of operating assets and liabilities in foreign currencies. And for this quarter, we had a negative impact on results. So just over 5 million SEK was attributable to this revaluation compared to a positive of just under 2 million last year. Following this, our operating profit, our EBIT for the quarter was 23 million SEK, corresponding to an operating margin of 10%. If we then adjust our PNL for FX effects, EBIT amounted to 36 million or 14%. And the way we did this is then that we did so. We used the average exchange rate for Q1 last year and recalculated the PNL. However, balance sheet items and their impact on this line have not been restated. The other operating income and expense line that has not been restated. Organization-wise, the number of employees at the end of the period was 317. That's 19 less than going out of Q1 last year. And the majority of this change is attributable to the restructuring of the sales force following the acquisition of Intuitive and also the closing of the Seattle office in Q4 last year. For Adjusted EBIT, which is EBIT exclusive of amortization on surplus values related to acquisitions. The result here for the quarter was 28 million. And if we then adjust for FX effects the same way as we did for EBIT, our Adjusted EBIT was 42 million or 16%. Finance, net and taxes. Not much to say here for the quarter. We have no loan financing, meaning that the net financial items mainly consist of interest income on bank deposits. And also we have revaluation of internal loan liabilities to subsidiaries and an IFRS 16 effect. Net profit for the quarter was 19 million, and the tax expense was 3 million. For this year. There are tax loss carryforwards in the US attributable to Mimic and also in the UK attributable to Surgical Science UK. And then cash flow. We saw a very strong quarter on the cash flow side, 65 million from operating activities compared with minus five last year. We had a big positive from working capital, 36 million, where inventory remained largely unchanged, while accounts receivable decreased, specifically current receivables, including accrued income. And that mainly relates to accrued license revenues that we invoice and that are paid in the following quarter. That has also decreased, meaning a positive effect on the cash flow. Investing activities. Tom talked about our new production facility in Tel Aviv. And for this quarter, we invested approximately 6 million. And as also mentioned, they are expected to be commissioned now in the second quarter. Financing activities are not much to mention here for the quarter. And that meant that cash flow was a positive 51 million for the quarter. And we ended the quarter with 668 million in our cash and equivalents. And with that, we open up for questions.

Tom Englund
25:27 - 26:47

I would like to conclude by first thanking Ana and then a short wrap up. Quarter one was a solid quarter for Surgical Science. The underlying business is growing. Margins are in line with last year, and cash flow was the best quarter one we've had in some time. The currency environment has been a real headwind, and the Intuitive impact on the license revenue is playing out as expected. But if you look through those two factors, what you see is a company executing well. We have momentum in EMEA. We have a very strong quarter in the U.K. We have exciting new product launches generally, and specifically in Ultrasound. We have a growing robotics ecosystem beyond Intuitive and a pricing strategy that is working. We are not yet at our financial targets. We have been clear that 2027 is the year we expect to hit them, but we're moving in the right direction and building the foundation that gets us there. The opportunity in front of Surgical Science is significant. Simulation will become a central part of how healthcare trains its professionals. And we intend to lead that shift. With that, we open the floor for questions.

Anna Berry
26:48 - 26:49

Thanks, Tom.

Operator
26:50 - 27:09

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Christiane from Pareto Securities. Please go ahead.

Christiane
27:11 - 27:47

Yes. Good morning, Tom, and thank you for taking my two questions. The first is regarding the license revenue. If you could give us some color on the composition of the license revenue in the quarter, if there were any larger packages delivered in Q1. And given that your robotics customers, aside from Intuitive, are contributing to sales to a great extent, do you view the 67 million you had in Q1 as a floor for the license revenue, or should we expect continued volatility going forward?

Tom Englund
27:50 - 29:41

I mean, hi, Christiane. Good question. So regarding the license revenues, it is clearly a positive trend where, as I said, simulation will play a central part of the digital offerings of the robotics platforms in the future. And since there are many players now entering the competition, more robotics systems are out there, the market is growing, and the market potential is growing for simulation. That's clear. And I think it's very positive that we see that revenue streams from several different customers were seen during the quarter. Then regarding Intuitive and the expectations going forward, we don't speak about specific customers, but what we can say is that simulation continues to be an important piece of the digital offering of Intuitive. In a sense there, you could say that 2025 with a 100% attach rate on the DFI was a slight jump start of the future. But when we speak with all our robotics customers, the team and I see that the discussions are only about how they can expand simulation content for their platforms and how they can tie simulation even more closely into their training pathways for the surgeons. So there is a real gap here between installed capacity of robotic systems and the number of trained surgeons. So that's why I say that not only will we be an important piece for the robotics platform. But also, we think that this will be a growing opportunity. Growing business for us. Exactly how this will play out quarter by quarter is difficult to say, but I think you have to find appeal in the long-term opportunity here.

Christiane
29:45 - 30:01

Excellent. Thank you. My second question is regarding the structural changes in the Chinese market and your steps to address these challenges. And are you considering moving any manufacturing or perhaps assembly operations to China?

Tom Englund
30:02 - 30:56

It's a very good question. And it's definitely a structural shift. And what we are doing is that we are trying to apply a term coined by Atlas Copco, 'Glocal', meaning that we want to be global and local at the same time. So what this means is that we want to have more local presence, generally speaking, in China, not just related to production or operations. We want to be perceived as one global important player with a very strong local foundation, so that we can be seen as an attractive player from a Chinese perspective and not as a foreign company. So we're taking actions then to increase our presence generally in China. And that has had as an effect, several important decisions here through last quarter and also this quarter.

Christiane
31:00 - 31:01

Great. Thank you very much.

Operator
31:06 - 31:10

The next question comes from Simon Larsson from Danske Bank. Please go ahead.

Simon Larsson
31:12 - 31:52

Yes. Hi, Tom and Emma. I would like to start on the Educational segment. I think it was a rather solid quarter for that part of the business. And it seems, looking back a couple of quarters now, that you've established some kind of revenue level, around 130 million per quarter. So how should we think about the Edu segment in particular going forward? Is this some kind of floor level you believe, or any meaningful one-off here in Q1 that shouldn't be extrapolated, thinking maybe about the Ultrasound business, which was very strong, obviously? But any help on the dynamics on the Educational Products segment here going forward would be helpful.

Tom Englund
31:53 - 33:57

So we haven't, as you know, particularly explained or set specific target for the Educational segment in the new financial target. But rather, we had financial targets for the entire company at the group level. But the segment is definitely an under-penetrated segment and there is lots of opportunity for growth there. And within the different subsegments of the segment, there is different growth potential, both in percentage and absolute terms. The way we're going to grow this segment is primarily by two important levers. One is the sales and marketing lever, driving awareness in this segment of medical simulation and the value of our products. That's mainly a sales and marketing effort. And there we have a tremendous amount of activities going into driving different types of marketing initiatives to drive awareness, as well as thinking hard and executing on how to cover the market in a much better way. We have a very broad product portfolio today, and there is a big opportunity here to cover the market in a more efficient way. And the second growth lever is in new product introductions. And as I mentioned in my, my, my comment here, we have a strong product pipeline working within R&D and product development. And we also have made some important product announcements here last quarter and the quarter before that as well. And usually, what happens then is that it becomes an add-on effect, meaning that it doesn't take away from the existing business. It rather adds onto the business. So when you introduce a new product, then you get a jump in the sales. So it's definitely a growth strategy. And we're working on these two to three levers: sales, marketing, and product development, to increase the penetration and grow the sales.

Simon Larsson
33:59 - 34:35

Yeah. Cool. Gotcha, gotcha. And I suppose maybe a tough question to answer, but on the industry OEM side, as Christian also mentioned, the strong print here in Q1 and you're sticking to your 60 to 90 million impact versus last year for the full year of 26. But could you give us any direction as to how the impact will be distributed over the quarters, I would expect to see increased pressure from Intuitive in the coming quarters, or am I mistaken? Any help in that regard appreciated.

Tom Englund
34:36 - 35:53

I think there are a lot of moving parts here. It's not just with our license revenues. Revenues are not just constituted of Intuitive alone. As I've said, we have several different revenue streams within license revenues. We want to stick to the overarching argument that simulation will become a very central piece for the robotics manufacturing. As I said, we see an increase in the number of requests for proposals and the number of development projects that we have with these customers. And usually, they become customers and stay with us for a long time. Additionally, robotics manufacturers themselves work on the business modeling and the packaging of their digital offerings, and the way robotic platforms are offered tomorrow will not necessarily be the same as today. And that will also have an impact on the packaging of the digital offerings. And it will also have an impact on the volume of licenses that we sell. So there are so many moving parts here. So we want to refrain from making any more specific predictions, but rather stick to the 60 to 90 million that we have said. That is the impact on the full year. And then feel very confident about the long term opportunity here in the license business.

Simon Larsson
35:56 - 35:57

Understood. Thanks so much.

Operator
36:00 - 36:14

As a reminder, if you wish to ask a question, please dial pound key on your telephone keypad. The next question comes from Ulrich Trattner from NB Carnegie. Please go ahead.

Ulrich Trattner
36:16 - 36:53

Thank you very much. Building on previous questions. And regarding the 60 to 90 million in guidance you provided, is there any way where you can give us some more information on the effects in Q1? And I know you won't expand upon the guidance, but it should really help the market to navigate and understand the underlying growth in this segment. If you can help us provide some more granularity on that potential headwind or the expectation of headwinds throughout the course of 2026.

Tom Englund
36:53 - 38:32

Once again, I think it's very dangerous and somewhat unprofessional to try and give guidance on a quarter-by-quarter basis when there are so many moving parts. I think that the macro trends are very positive and strong. I spoke about the increase of competition with the different robotic manufacturers. Now, coming in, we see strong competition within the US market with Medtronic and Johnson & Johnson entering the fray. And that of course drives the need for training and the need for simulation. And then as I also mentioned here, just in the previous question, there are also moving parts in how you package and how you price these licenses and what prices you have for these licenses. All this together. And still, the relatively few customers – not having hundreds or thousands of license streams – makes it a little bit lumpy, but the longer-term opportunity is very strong. And we also feel very confident in our ability to deliver value and extract good solid prices from these customers. And more specifically, regarding, for example, the attach rate and how many licenses per system for specific customers. We need to also see how this plays out over a longer term. It's too early to judge for just one quarter.

Ulrich Trattner
38:34 - 38:42

Sure. But if I were to look isolated here for Q1, what was sort of the quantified negative effect year over year?

Anna Berry
38:45 - 39:10

Do you mean for Intuitive? We have never commented on the amount that we have for different customers. So again, we do stick to the 60 to 90. It's still our best estimate for the year. Looking then at 2026 in comparison to 2025.

Ulrich Trattner
39:12 - 39:21

So in essence, we will never be able to essentially track whether it's 60, 90, or 150 million in 2026.

Anna Berry
39:25 - 39:26

We will never.

Ulrich Trattner
39:27 - 39:45

Be able to assess, as we're on the sell side, trying to put down estimates. We will never be able to estimate or get any sense of whether it's 60 million, 90 million, 150 million, or 250 million in negative effects year over year.

Anna Berry
39:47 - 40:20

We had 300 million. We had 300 million in licensed revenues for last year. And, of course, Intuitive is a dominant player on the market. We cannot comment on the exact numbers, but of course, this is something that we will follow if we have the possibility to give more information down the line. When we see more quarters, we will, of course, continue to comment on this range.

Ulrich Trattner
40:24 - 41:05

Then, a follow-up question. Robotic surgery sales were down 17-18% in local currency in reported numbers year over year, with over 80% attributable to America. So, I guess there's a significant FX headwind; I would potentially estimate it to be around 10%. But then if you add back the negative effects, are we talking about underlying growth here in constant exchange rates, or is it still in negative territory?

Anna Berry
41:06 - 41:09

For the license revenues, if we look at them.

Ulrich Trattner
41:09 - 41:21

Robotic Surgery, since you're providing the revenue by product segment and Robotic Surgery is then isolated. So just in general, for the entire robotic surgery segment.

Anna Berry
41:22 - 42:06

Oh, yeah. Yeah, we do have sales of products there, of course, as well. For example, robotics, which is within the Educational Products segment, but licenses still represent the majority. And as Tom mentioned, that's down like 8%. And we saw that actually being higher than several of the other quarters last year. But Q1 was 14% down for the US dollar. Q1 really had a very large currency effect, which is slowly moving into Q2. It will be less if the dollar stays at this level. But yeah.

Ulrich Trattner
42:09 - 42:57

Okay. Great. And my second and final question, and I'm not sure if you want to answer this one. In the UK, you talk about success in the first quarter and some strong underlying demand and momentum out of that market? Intelligent ultrasound is part of this transformation and success in the UK. And given that we saw negative EBIT contribution from Intelligent Ultrasound throughout 2025, and there is a significant uptick here in EBIT for Q1 at least versus my expectations. Are we to assume that Intelligent Ultrasound is now a separate entity in the black on EBIT?

Tom Englund
42:58 - 43:58

Yeah, definitely. So they are contributing to our EBIT for this quarter, due to, of course, increased sales, but also through the cost reduction program that we have done as a part of the integration process. Apart from that, I also want to mention that we see an improved funding climate from the NHS that has made it possible to close many deals that have been frozen in the NHS. In the NHS purchasing department, and also the fact that we now have a direct sales team in the UK, which is selling the entirety, not just Intelligent Ultrasound products or ultrasound simulation products, but the entirety of the Surgical Science portfolio, has had a very important positive impact on the sales and will, of course, have an even more important impact on the sales going forward, both for educational and also for our industry customers in the UK, which represent a big opportunity for us.

Simon Larsson
44:01 - 44:01

Great.

Ulrich Trattner
44:02 - 44:05

That was all questions on my end, and I'll get back into the queue.

Tom Englund
44:05 - 44:06

Thank you.

Operator
44:13 - 44:20

There are no more questions at this time. So I hand the conference back to the speakers for any written questions or closing comments.

Anna Berry
44:20 - 45:43

Yes, great. I was just about to say we have some written questions. I think there was one about China. We answered that one. I hope there's one around the uplist and the timetable for that, taking place in 2027, for which a normal timetable for this process is around a year, depending, of course, on how many consultants, etc. you use as well. But as for the share buyback, which is connected to this question, we cannot today do a share buyback on First North Growth Market. However, it will be allowed starting in December this year, and that is why we... We. Tomorrow when we have the AGM, there is a proposal to the AGM to give us that mandate so that we have it when the uplift takes place, or if we're allowed on the First North Growth Market, then there is one more question also around the relationship with Intuitive. When you say, Tom, it's stronger than ever. Can you please elaborate? I think.

Tom Englund
45:44 - 46:45

The way these relationships work, not just with Intuitive but with both robotics companies as well as medtech companies, involves engaging in deep collaborative projects focused on a specific value, a specific feature, or a specific product from them. And then our development teams engage in a project. In a development project that leads to either a software simulation piece or some type of hardware for a medtech company. And these types of discussions with Intuitive are ongoing and development work is still continuing in an unchanged manner. And that's what I mean by this comment. And of course, that's a lead indicator for, for, for future business. Of course, both with this customer and with all the other customers that we have.

Anna Berry
46:47 - 46:51

Then I don't think we have any more written questions.

Tom Englund
46:56 - 47:03

No, no more questions. So thank you for your attention. And, see you all in a quarter.

Anna Berry
47:03 - 47:05

Thank you. Thank you for today.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…